SALT LAKE CITY, Feb. 16 /PRNewswire-FirstCall/ -- Diabetic Treatment Centers of America, Inc. (BULLETIN BOARD: DBTC) , announced today the execution of a Letter of Intent with Activate Your Metabolism.
“Activate Your Metabolism (AYM) provides an incredible therapy for the de-conditioned (disabled, elderly, and sedentary persons) market. This targets the early stage diabetic patient. Coupled with our Pulse Insulin Therapy for critical stage diabetics, we will now be able to provide quality medical care to a larger portion of the diabetic community,” said Arden Oliphant, CEO of Diabetic Treatment Centers of America, Inc.
“By combining the AYM program with the Diabetic Treatment Centers of America business platform, we begin to build a very exciting opportunity for diabetic sufferers. Diabetics will now be able to live more normal lifestyles, and enjoy a better quality of life,” said Patty Davis of Activate Your Metabolism.
The Letter of Intent which was executed by both parties provides for the negotiation of the final joint venture terms, is non-binding on both parties and subject to the completion of due diligence considered normal and customary in transactions of this type.
About Diabetic Treatment Centers of America
Based in Salt Lake City, Utah, DTC of America is dedicated to providing effective medical therapies to diabetics that will significantly improve their health and well being.
Safe Harbor Statement
This news release may include forward-looking statements within the meaning of Section 27a of the United States Securities Act of 1933, as amended, and Section 21e of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company’s analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.
Contact: Diabetic Treatment Centers of America, Inc. Arden Oliphant, 801-207-1816 aoliphant@dtcofamerica.com
Diabetic Treatment Centers of America, Inc.
CONTACT: Arden Oliphant of Diabetic Treatment Centers of America, Inc.,+1-801-207-1816, aoliphant@dtcofamerica.com